sb 216763 and morphine
sb 216763 has been researched along with morphine in 6 studies
Compound Research Comparison
| Studies (sb 216763) | Trials (sb 216763) | Recent Studies (post-2010) (sb 216763) | Studies (morphine) | Trials (morphine) | Recent Studies (post-2010) (morphine) |
|---|---|---|---|---|---|
| 342 | 0 | 225 | 44,270 | 5,200 | 8,695 |
Protein Interaction Comparison
| Protein | Taxonomy | sb 216763 (IC50) | morphine (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.2939 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.2278 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.0828 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0385 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0545 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.122 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1199 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.9308 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.655 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.3305 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.202 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.25 |
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Gross, ER; Gross, GJ; Hsu, AK | 2 |
| Makuch, W; Obara, I; Parkitna, JR; Przewlocka, B; Przewlocki, R; Wawrzczak-Bargiela, A | 1 |
| Assaly, R; Berdeaux, A; Dubois-Randé, JL; Morin, D; Obame, FN; Plin-Mercier, C; Zini, R | 1 |
| Chen, JY; Chen, KB; Liao, CC; Liao, WW; Tsai, SY; Wen, YR; Yeh, GC | 1 |
| Hall, FS; Igarashi, K; Kitanaka, J; Kitanaka, N; Sato, T; Tomita, K; Uhl, GR | 1 |
Other Studies
6 other study(ies) available for sb 216763 and morphine
| Article | Year |
|---|---|
Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts.
Topics: Aminophenols; Androstadienes; Animals; Benzamides; Cardiotonic Agents; Chromones; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Indoles; Male; Maleimides; Morphine; Morpholines; Myocardial Infarction; Narcotic Antagonists; Nuclear Receptor Subfamily 1, Group F, Member 3; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Premedication; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Retinoic Acid; Receptors, Thyroid Hormone; Signal Transduction; Sirolimus; Wortmannin | 2004 |
Effects of glycogen synthase kinase 3beta and cyclin-dependent kinase 5 inhibitors on morphine-induced analgesia and tolerance in rats.
Topics: Analgesia; Analgesics, Opioid; Animals; Cyclin-Dependent Kinase 5; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Tolerance; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Indoles; Male; Maleimides; Morphine; Pain Threshold; Rats; Rats, Wistar; Spinal Cord | 2006 |
GSK3beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion.
Topics: Analgesics, Opioid; Androstadienes; Animals; Benzamides; Benzopyrans; Blood Pressure; Cardiotonic Agents; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanidines; Heart Rate; Imidazoles; Indoles; Ion Channel Gating; Male; Maleimides; Morphine; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Potassium Channel Blockers; Potassium Channels; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sarcolemma; Signal Transduction; Time Factors; Wortmannin | 2007 |
Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3 beta, SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via inhibition of the mitochondrial permeability transition pore.
Topics: Animals; Cardiotonic Agents; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Indoles; Intracellular Membranes; Male; Maleimides; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Morphine; Myocardial Infarction; Permeability; Rats; Rats, Wistar | 2008 |
Coadministration of glycogen-synthase kinase 3 inhibitor with morphine attenuates chronic morphine-induced analgesic tolerance and withdrawal syndrome.
Topics: Aminophenols; Animals; Drug Combinations; Drug Tolerance; Glycogen Synthase Kinase 3; Indoles; Male; Maleimides; Morphine; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome | 2014 |
Glycogen Synthase Kinase-3 Inhibitors Block Morphine-Induced Locomotor Activation, Straub Tail, and Depression of Rearing in Mice Via a Possible Central Action.
Topics: Animals; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Mice; Morphine; Tail | 2023 |